John T Cavan - Net Worth and Insider Trading
John T Cavan Net Worth
The estimated net worth of John T Cavan is at least $340 dollars as of 2024-12-28. John T Cavan is the CFO of Hepion Pharmaceuticals Inc and owns about 740 shares of Hepion Pharmaceuticals Inc (HEPA) stock worth over $340. Details can be seen in John T Cavan's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that John T Cavan has not made any transactions after 2021-02-18 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of John T Cavan
John T Cavan Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, John T Cavan owns 2 companies in total, including Hepion Pharmaceuticals Inc (HEPA) , and Aegerion Pharmaceuticals Inc (AEGR) .
Click here to see the complete history of John T Cavan’s form 4 insider trades.
Insider Ownership Summary of John T Cavan
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| HEPA | Hepion Pharmaceuticals Inc | 2021-02-18 | Chief Financial Officer |
| AEGR | Aegerion Pharmaceuticals Inc | 2010-10-21 | VP & Chief Accounting Officer |
John T Cavan Latest Holdings Summary
John T Cavan currently owns a total of 1 stock. John T Cavan owns 740 shares of Hepion Pharmaceuticals Inc (HEPA) as of February 18, 2021, with a value of $340.
Latest Holdings of John T Cavan
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals Inc | 2021-02-18 | 740 | 0.46 | 340 |
Holding Weightings of John T Cavan
John T Cavan Form 4 Trading Tracker
According to the SEC Form 4 filings, John T Cavan has made a total of 2 transactions in Hepion Pharmaceuticals Inc (HEPA) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Hepion Pharmaceuticals Inc is the acquisition of 500 shares on February 18, 2021, which cost John T Cavan around $20,000.
Insider Trading History of John T Cavan
- 1
John T Cavan Trading Performance
GuruFocus tracks the stock performance after each of John T Cavan's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by John T Cavan is -7.98%. GuruFocus also compares John T Cavan's trading performance to market benchmark return within the same time period. The performance of stocks bought by John T Cavan within 3 months outperforms 1 times out of 3 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how John T Cavan's insider trading performs compared to the benchmark.
Performance of John T Cavan
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 7.61 | | | | | |
| Relative Return to S&P 500(%) | 6.42 | | | | | |
John T Cavan Ownership Network
John T Cavan Owned Company Details
What does Hepion Pharmaceuticals Inc do?
Who are the key executives at Hepion Pharmaceuticals Inc?
John T Cavan is the Chief Financial Officer of Hepion Pharmaceuticals Inc. Other key executives at Hepion Pharmaceuticals Inc include Chief Scientific Officer Robert T Foster , director & CEO and President Gary S Jacob , and 10 percent owner Donald E Garlikov .
Hepion Pharmaceuticals Inc (HEPA) Insider Trades Summary
Over the past 18 months, John T Cavan made no insider transaction in Hepion Pharmaceuticals Inc (HEPA). Other recent insider transactions involving Hepion Pharmaceuticals Inc (HEPA) include a net purchase of 8,000 shares made by Peter Wijngaard , and a net purchase of 3,200 shares made by Robert T Foster .
In summary, during the past 3 months, insiders sold 0 shares of Hepion Pharmaceuticals Inc (HEPA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Hepion Pharmaceuticals Inc (HEPA) were sold and 11,200 shares were bought by its insiders, resulting in a net purchase of 11,200 shares.
Hepion Pharmaceuticals Inc (HEPA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Hepion Pharmaceuticals Inc Insider Transactions
John T Cavan Mailing Address
Above is the net worth, insider trading, and ownership report for John T Cavan. You might contact John T Cavan via mailing address: C/o Stemline Therapeutics, Inc., 750 Lexington Avenue, 6th Floor, New York Ny 10022.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
